Status:
UNKNOWN
Prognostic Value Of Lymphocyte Count and Lymphocyte/ Monocyte Ratio in Patients With Hodgkin's Lymphoma
Lead Sponsor:
Tishreen University
Conditions:
Hodgkin Lymphoma
Eligibility:
All Genders
15+ years
Brief Summary
This study is to assess the utility of using Absolute Lymphocyte count, Lymphocyte/Monocyte Ratio and International Prognostic Scote at diagnosis in Hodgkin's Lymphoma as a prognostic predictor of the...
Detailed Description
Hodgkin's Lymphoma has a high cure rate even if patients do not complete their treatment, this proposes that some patients may experience overtreatment and that would have negative effects (such as ca...
Eligibility Criteria
Inclusion
- Newly diagnosed patients with Hodgkin's Lymphoma who have not yet received treatment
- Ages over 16 years old
- Signed informed consent before registration in study
Exclusion
- Patients who have already received treatment
- Patients with a previous history of malignancy
- Patients with autoimmune diseases
- Patients with primary immunodeficiency
- AIDS patients
- Patients with acute or chronic infections
- Patients treated with drugs that affect the result of the analysis (Corticosteroids, Immunosuppressants, Li)
Key Trial Info
Start Date :
January 4 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04893538
Start Date
January 4 2021
End Date
July 1 2022
Last Update
March 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tishreen University
Latakia, Syria